Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation

Abstract

In patients undergoing HSCT, routine prophylaxis with IVIG is not supported. Its use may be considered in LPD patients with hypogammaglobulinemia and recurrent infections, for reduction of clinically documented infections.

Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality

“…Furthermore, the incidence of veno-occlusive disease was slightly increased in the cohort with high dose IVIG (16). A recently published Cochrane Analysis of 40 studies did not find a benefit of IVIG either (38). Our data are in line with these findings.…”

Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality

“…Furthermore, the incidence of veno-occlusive disease was slightly increased in the cohort with high dose IVIG (16). A recently published Cochrane Analysis of 40 studies did not find a benefit of IVIG either (38). Our data are in line with these findings.…”

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

“…15 This is consistent with the NIH consensus paper recommendations. 16 Despite these considerations, until now only a few studies have evaluated the potential prophylactic role of polyvalent immunoglobulins in hypogammaglobulinemic patients with LPDs.…”

Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia

“…Chapel et al ( 17 ) in 1994 performed a randomized, double-blind, placebo-controlled, multicenter trial of IVIG employed as prophylaxis against infection in 82 patients with stable MM; the authors demonstrated a protective role of IVIG against life-threatening infections and a significant role in reducing the risk of recurrent infections. Other two studies have been performed in patients with hypogammaglobulinemia and either CLL or MM, obtaining similar results ( 6 ). Conversely, Blombery et al ( 18 ) showed no benefit of the use of peritransplant IVIG to reduce infectious complications in hypogammaglobulinemic patients with MM undergoing autologous stem cell transplantation.…”

Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality

“…Furthermore, the incidence of veno-occlusive disease was slightly increased in the cohort with high dose IVIG (16). A recently published Cochrane Analysis of 40 studies did not find a benefit of IVIG either (38). Our data are in line with these findings.…”

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

“…15 This is consistent with the NIH consensus paper recommendations. 16 Despite these considerations, until now only a few studies have evaluated the potential prophylactic role of polyvalent immunoglobulins in hypogammaglobulinemic patients with LPDs.…”

Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia

“…Chapel et al ( 17 ) in 1994 performed a randomized, double-blind, placebo-controlled, multicenter trial of IVIG employed as prophylaxis against infection in 82 patients with stable MM; the authors demonstrated a protective role of IVIG against life-threatening infections and a significant role in reducing the risk of recurrent infections. Other two studies have been performed in patients with hypogammaglobulinemia and either CLL or MM, obtaining similar results ( 6 ). Conversely, Blombery et al ( 18 ) showed no benefit of the use of peritransplant IVIG to reduce infectious complications in hypogammaglobulinemic patients with MM undergoing autologous stem cell transplantation.…”

Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality

“…Furthermore, the incidence of veno-occlusive disease was slightly increased in the cohort with high dose IVIG (16). A recently published Cochrane Analysis of 40 studies did not find a benefit of IVIG either (38). Our data are in line with these findings.…”

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

“…15 This is consistent with the NIH consensus paper recommendations. 16 Despite these considerations, until now only a few studies have evaluated the potential prophylactic role of polyvalent immunoglobulins in hypogammaglobulinemic patients with LPDs.…”

Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia

“…Chapel et al ( 17 ) in 1994 performed a randomized, double-blind, placebo-controlled, multicenter trial of IVIG employed as prophylaxis against infection in 82 patients with stable MM; the authors demonstrated a protective role of IVIG against life-threatening infections and a significant role in reducing the risk of recurrent infections. Other two studies have been performed in patients with hypogammaglobulinemia and either CLL or MM, obtaining similar results ( 6 ). Conversely, Blombery et al ( 18 ) showed no benefit of the use of peritransplant IVIG to reduce infectious complications in hypogammaglobulinemic patients with MM undergoing autologous stem cell transplantation.…”